← Back to headlines
Novartis Faces Drug Pipeline Scrutiny Amid Valuation Premium Focus
Pharmaceutical giant Novartis is under pressure to prove the strength of its drug pipeline as its valuation premium comes under investor focus.
20 Jul, 05:07 — 20 Jul, 05:07
Sources
Showing 1 of 1 sources
Related Stories
Banks Pause Sales of Products Linked to Mark Walter Amid Investigations
53m ago
Rating Agencies Maintain Stable Outlooks for French and Portuguese Sovereign Debt
56m ago
Canada’s Economy Rebounds With 3.3% Growth in Second Quarter
1h ago
FDA Approves Takeda's Mimrylo for Blood Cancer Condition Polycythemia Vera
1h ago